NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-10-30 13:16இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
TTK Healthcare Q2 Net Profit Jumps to ₹222.97 Cr Aided by ₹248.20 Cr Brand Divestment Gain
TTK Healthcare reported its Q2 FY2026-27 results with revenue from operations reaching ₹233.38 Cr, up 14.6% YoY from ₹203.57 Cr. Reported net profit rose sharply to ₹222.97 Cr compared to ₹20.39 Cr in Q2 FY2025, driven by an exceptional net gain of ₹248.20 Cr on the sale of 'EVA' and 'GoodHome' brands to Wipro Enterprises for ₹256 Cr. Excluding exceptional items and taxes, profit before exceptional items and tax stood at ₹19.74 Cr versus ₹21.30 Cr YoY. The company received the ₹256 Cr cash consideration on September 4, 2026, boosting its cash and investment reserves.
உச்சம் நம்பிக்கை
என்ன மாறியதுCompleted the sale of 'EVA' and 'GoodHome' brands to Wipro Enterprises for ₹256 Cr, recognizing a ₹248.20 Cr net exceptional gain in Q2 FY2026-27.
ஏன் இது முக்கியம்The brand sale significantly boosts cash balances and reported net worth but removes brand revenue streams, focusing operations on remaining core FMCG and medical devices segments.
Revenue from Operations (Q2): ₹23,338.39 லட்சம்Net Profit (PAT) (Q2): ₹22,297.26 லட்சம்Brand Sale Consideration: ₹25,600 லட்சம்Exceptional Net Gain: ₹24,820.03 லட்சம்Sale Value vs TTM Revenue: ~28.8%
📅 குறுகிய காலம்Earnings optically surge due to one-off brand sale proceeds; market attention will focus on underlying operating profitability and cash utilization plans.
📈 நீண்ட காலம்The company's balance sheet is further de-leveraged and cash-rich, though long-term growth hinges on effectively redeploying large cash reserves into higher-return avenues.
⚠ அபாய எச்சரிக்கைகள்
One-off gain distorts bottom-line comparability
Loss of revenue from divested consumer brands EVA and GoodHome
Core operating profit before tax fell ~7.3% YoY
👀 கவனிக்க வேண்டியவை
Track the deployment of the substantial cash generated from brand divestments toward potential acquisitions or core business expansion, along with organic operational margin performance in upcoming quarters.
TTK Healthcare Completes Sale of EVA & Good Home Brands for ₹256 Cr Cash
TTK Healthcare has completed the sale of its 'EVA' and 'Good Home' brands to Wipro Enterprises Private Limited, receiving a cash consideration of ₹256 crore plus applicable GST. The transaction closes the definitive agreement executed on July 23, 2026. The ₹256 crore cash inflow represents approximately 29.9% of TTM revenue (₹857 crore) and 16.4% of the company's market capitalization (₹1,557 crore). This significantly boosts the company's existing cash reserves, which previously stood high following its human pharma divestment.
உச்சம் நம்பிக்கை
என்ன மாறியதுTTK Healthcare successfully closed the transaction and received ₹256 crore in cash from Wipro Enterprises for the transfer of 'EVA' and 'Good Home' brands.
ஏன் இது முக்கியம்The ₹256 crore cash infusion significantly bolsters the balance sheet and liquidity, though it will reduce consumer division revenue going forward as these brands are handed over.
Cash consideration received: Rs.256 croresDeal value vs Market cap: ~16.4%Deal value vs TTM revenue: ~29.9%Agreement date: ஜூலை 23, 2026Closing date: செப்டம்பர் 04, 2026
📅 குறுகிய காலம்Positive for stock sentiment due to the substantial cash realization and closure of the deal with Wipro Enterprises.
📈 நீண்ட காலம்The company's core operations narrow down to Gripe Water, contraceptives, medical devices, and foods, with a very large cash kitty available for redeployment or shareholder distribution.
⚠ அபாய எச்சரிக்கைகள்
Loss of revenue and operating profit contribution from the divested EVA and Good Home product lines
Reinvestment risk regarding the large cash reserves
👀 கவனிக்க வேண்டியவை
Watch for management commentary in the upcoming quarterly results regarding capital allocation plans, special dividend distribution, or potential redeployment of the cash surplus.
63% PAT Growth in Q1; TTK Healthcare to Sell EVA & Good Home Brands for Rs 256 Cr
TTK Healthcare reported a strong Q1 FY26 with revenue growing 13.7% YoY to Rs 257.56 Cr and PAT rising 63.7% to Rs 21.28 Cr. A major highlight is the definitive agreement to sell the 'EVA' and 'Good Home' brands to Wipro Enterprises for Rs 256 Cr, representing approximately 30% of TTM revenue. The company also successfully recovered Rs 5.10 Cr from previously written-off USAID orders in the Protective Devices segment. Profitability was significantly bolstered by a turnaround in the Protective Devices division, which moved from a loss to a Rs 6.13 Cr profit.
உச்சம் நம்பிக்கை
என்ன மாறியதுTTK Healthcare has formalized a major brand divestment and demonstrated a sharp operational recovery in its Protective Devices (contraceptives) segment.
ஏன் இது முக்கியம்The Rs 256 Cr cash inflow (approx. 16.6% of market cap) significantly strengthens an already low-debt balance sheet and allows the company to focus on its remaining core segments or new acquisitions.
Q1 FY26 Revenue: Rs 257.56 கோடிQ1 FY26 PAT: Rs 21.28 கோடிBrand Sale Consideration: Rs 256 கோடிSale Value vs TTM Revenue: ~30%USAID Order Recovery: Rs 5.10 கோடி
📅 குறுகிய காலம்The stock is likely to react positively to the strong earnings growth and the substantial cash realization from the brand sale.
📈 நீண்ட காலம்The company is transitioning its portfolio; the primary long-term value driver will be the effective deployment of its massive cash pile (divestment proceeds plus existing surplus).
⚠ அபாய எச்சரிக்கைகள்
Loss of revenue and margins from the divested high-profile brands (EVA/Good Home)
Execution risk in reinvesting the large cash surplus effectively
👀 கவனிக்க வேண்டியவை
Monitor the completion of the Rs 256 Cr brand sale by September 30, 2026, and watch for management commentary on the deployment of the resulting cash surplus.
₹256 Cr Brand Divestment and ₹900 Cr Cash Surplus Highlighted at 68th AGM
TTK Healthcare reported FY26 revenue of ₹857.28 cr, a 7% growth, though pre-tax profit fell to ₹82.56 cr due to the loss of USAID tender business in the Protective Devices segment. The company announced the divestment of its 'EVA' and 'Good Home' brands to Wipro Enterprises for ₹256 cr, which contributed ₹148 cr to FY26 revenue. Most notably, the company now holds a massive cash balance of ~₹900 cr, representing approximately 61% of its current market capitalization. A dividend of ₹10 per share (100%) was recommended.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company is divesting two major consumer brands (EVA and Good Home) and has significantly increased its cash reserves to ₹900 cr.
ஏன் இது முக்கியம்The brand sale represents ~30% of TTM revenue and provides a massive liquidity cushion, though it creates a temporary revenue gap that needs to be filled by other segments like Ortho or new acquisitions.
Brand Divestment Value: ₹256 கோடிDivestment vs TTM Revenue: ~30%Cash Balance: ₹900 கோடிCash vs Market Cap: ~61%FY26 Revenue Growth: 7%Dividend per Share: ₹10.00
📅 குறுகிய காலம்The stock may see positive sentiment due to the high valuation achieved for the brand divestment and the substantial cash-per-share floor.
📈 நீண்ட காலம்The company is undergoing a structural shift, moving away from certain consumer segments toward medical devices and animal welfare; long-term value depends on the efficient allocation of the ₹900 cr cash pile.
⚠ அபாய எச்சரிக்கைகள்
Loss of high-margin institutional/tender business (USAID)
Revenue concentration risk following brand divestments
Execution risk in clinical trials for new medical devices
👀 கவனிக்க வேண்டியவை
Monitor the deployment strategy for the ₹900 cr cash surplus, as the company continues to divest non-core brands. Investors should track the margin impact of losing the ₹148 cr consumer brand revenue versus the interest income or acquisition potential from the new cash inflow.
Rs 256 Cr Brand Sale: TTK Healthcare to Divest EVA and Good Home Brands to Wipro
TTK Healthcare has entered into a definitive agreement to sell its 'EVA' and 'Good Home' brands to Wipro Enterprises Private Limited for a total consideration of Rs 256 crore. These brands contributed approximately Rs 148 crore to the company's FY26 revenue, representing 17% of its total turnover. The transaction is expected to close by September 30, 2026, and will significantly increase the company's already substantial cash reserves. This move follows the company's previous large-scale divestment of its human pharma division.
உச்சம் நம்பிக்கை
என்ன மாறியதுTTK Healthcare is exiting the personal care (EVA) and home care (Good Home) segments by selling these brands to Wipro Enterprises.
ஏன் இது முக்கியம்The sale unlocks significant value for brands that were contributing 17% of revenue but likely required high marketing spend. The company is now extremely cash-rich relative to its market cap, shifting the investment thesis toward capital allocation and potential new acquisitions.
Sale Consideration: Rs 256 கோடிBrand Revenue (FY26): Rs 148 கோடிRevenue Contribution %: 17%Deal Value vs Market Cap: ~18%Expected Completion Date: செப்டம்பர் 30, 2026
📅 குறுகிய காலம்The stock is likely to react positively to the cash infusion and the valuation multiple achieved for the brands (approx 1.7x brand revenue).
📈 நீண்ட காலம்The company is structurally transforming into a cash-heavy entity. Long-term performance depends on whether management can reinvest the ~Rs 1,000+ cr cash pile into higher-margin businesses than the divested segments.
⚠ அபாய எச்சரிக்கைகள்
Loss of 17% of total revenue
Reinvestment risk of large cash balances
Increased dependence on remaining niche segments like contraceptives and gripe water
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's strategy for deploying its massive cash surplus, which now exceeds Rs 1,000 crore including previous divestment proceeds, as this will be the primary driver of future value.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
TTK Healthcare Sets July 17, 2026, as Record Date for Dividend and 68th AGM
TTK Healthcare Limited has announced July 17, 2026, as the record date for determining shareholder eligibility for its upcoming dividend and voting rights. The company's 68th Annual General Meeting (AGM) is scheduled to take place on July 24, 2026, at 12:00 PM via video conferencing. Shareholders must hold the stock by the record date to be eligible for the dividend payout and to participate in the voting process for corporate resolutions.
முக்கிய அம்சங்கள்
Record date for dividend and voting rights fixed for July 17, 2026.68th Annual General Meeting (AGM) scheduled for July 24, 2026, at 12:00 PM.AGM to be conducted via Video Conferencing (VC) or Other Audio-Visual Means (OAVM).Shareholders listed as of the cut-off date (July 17) will be eligible for the dividend distribution.
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend should ensure they hold the shares before the ex-dividend date, which typically precedes the July 17 record date. Existing shareholders should also prepare to participate in the virtual AGM to stay informed on company governance.
TTK Healthcare FY26 Revenue Up 7% to ₹857 Cr; Recommends ₹10 Dividend
TTK Healthcare reported a steady 7% growth in annual revenue from operations, reaching ₹857.28 crore for FY26. Net profit for the year declined to ₹65.68 crore from ₹81.66 crore in FY25, primarily due to a high base effect from a ₹19.77 crore land sale profit in the previous year. The Board has recommended a dividend of ₹10 per share (100% of face value). Additionally, the company has reappointed Mr. T T Raghunathan as Executive Chairman for a further five-year term starting November 2026.
முக்கிய அம்சங்கள்
Revenue from operations grew 6.96% YoY to ₹857.28 crore in FY26 compared to ₹801.49 crore in FY25.Net Profit for the year stood at ₹65.68 crore with an EPS of ₹46.48, down from ₹81.66 crore in the previous year.Recommended a final dividend of ₹10 per equity share (100%) for the financial year ended March 31, 2026.Recognized an exceptional income of ₹350.41 lakhs in Q4 FY26 pertaining to GST refunds from earlier periods.Total Assets increased to ₹1,328.74 crore as of March 31, 2026, up from ₹1,281.19 crore in the previous year.
👀 கவனிக்க வேண்டியவை
The profit decline is primarily due to non-recurring gains in the previous year rather than operational deterioration; investors should focus on the steady revenue growth and consistent dividend payout. Monitor the impact of the new Wage Structure implementation planned for FY 2026-27.
TTK Healthcare FY26 Net Profit Drops 19.5% to ₹65.68 Cr; ₹10 Dividend Declared
TTK Healthcare reported a 7% year-on-year growth in revenue from operations to ₹857.28 crore for FY26. However, net profit for the year declined significantly to ₹65.68 crore from ₹81.66 crore in FY25, primarily due to higher expenses and exceptional items. The company recognized a net exceptional charge of ₹7.58 crore related to the incremental impact of new Labour Codes on employee benefits. Despite the profit dip, the board has recommended a dividend of ₹10 per equity share (100% of face value).
முக்கிய அம்சங்கள்
Revenue from operations increased 7% YoY to ₹857.28 crore in FY26 compared to ₹801.49 crore in FY25.Net profit for FY26 fell to ₹65.68 crore, down from ₹81.66 crore in the previous fiscal year.Earnings Per Share (EPS) declined to ₹46.48 from ₹57.79 in the prior year.Recommended a dividend of ₹10 per equity share (100%) for the financial year ended March 31, 2026.Exceptional items included a ₹7.58 crore charge for Labour Code compliance and a ₹3.50 crore GST refund.
👀 கவனிக்க வேண்டியவை
Investors should be cautious as the decline in profitability and EPS suggests margin pressure despite revenue growth. Monitor the impact of the new wage structure and labour codes on future operating margins.
TTK Healthcare FY26 Revenue Rises 7% to ₹857 Cr; Declares ₹10 Dividend per Share
TTK Healthcare reported a steady 7% YoY growth in annual revenue to ₹857.28 crore for FY26. However, Profit After Tax (PAT) declined by 19.5% to ₹65.68 crore from ₹81.66 crore in FY25, primarily due to a net exceptional charge of ₹4.07 crore and a high base effect from the previous year's exceptional gains. The company has recommended a dividend of ₹10 per share (100%) and approved the reappointment of Mr. T T Raghunathan as Executive Chairman for another five-year term.
முக்கிய அம்சங்கள்
Annual Revenue from Operations increased to ₹857.28 crore in FY26 compared to ₹801.49 crore in FY25.Net Profit for FY26 stood at ₹65.68 crore, down from ₹81.66 crore in the previous year.Recommended a dividend of ₹10 per equity share of ₹10 each for the financial year ended March 31, 2026.Exceptional items for FY26 included a ₹7.58 crore charge for Labour Code adjustments, partially offset by a ₹3.50 crore GST refund.Executive Chairman T T Raghunathan reappointed for a 5-year term effective November 1, 2026.
👀 கவனிக்க வேண்டியவை
Investors should focus on the steady top-line growth while monitoring the impact of rising operational expenses on margins. The consistent dividend payout remains a positive for long-term shareholders.
TTK Healthcare Q3 Net Profit Drops 37% to ₹10.53 Cr; Impacted by ₹7.58 Cr Exceptional Item
TTK Healthcare reported a 37% year-on-year decline in net profit for Q3 FY26, falling to ₹10.53 crore from ₹16.73 crore. While revenue remained relatively flat at ₹209.30 crore, the bottom line was severely impacted by a one-time exceptional charge of ₹7.58 crore related to the implementation of new Labour Codes. Segment-wise, the Consumer Products and Medical Devices divisions saw margin pressure, while the Protective Devices division continued to report losses. On a positive note, the Foods and Animal Welfare segments showed improved profitability during the quarter.
முக்கிய அம்சங்கள்
Revenue from operations grew marginally by 2.2% YoY to ₹209.30 crore compared to ₹204.74 crore.Net profit declined 37% YoY to ₹10.53 crore, primarily due to a ₹7.58 crore exceptional charge for labour code adjustments.Consumer Products segment profit fell sharply to ₹2.25 crore from ₹6.45 crore in the previous year's quarter.Protective Devices segment recorded a loss of ₹1.10 crore, widening from a loss of ₹0.31 crore YoY.The company reconstituted its board committees following the retirement of Independent Director Mr. N Ramesh Rajan.
👀 கவனிக்க வேண்டியவை
Investors should monitor the recovery in the Consumer Products segment and the narrowing of losses in the Protective Devices division. While the profit dip is largely due to a non-recurring regulatory charge, the underlying operational weakness in core segments warrants a cautious approach.
TTK Healthcare Appoints Former TTK Prestige CFO V Sundaresan as Independent Director
TTK Healthcare has appointed Mr. V Sundaresan as an Additional Independent Director for a five-year term effective December 22, 2025. Mr. Sundaresan is a veteran professional with nearly 40 years of experience, including a 30-year tenure within the TTK Group where he served as the CFO of TTK Prestige Ltd. The appointment is subject to shareholder approval via a postal ballot process, with voting concluding on January 24, 2026. His deep expertise in corporate finance, audit, and internal controls is expected to enhance the company's governance framework.
முக்கிய அம்சங்கள்
Appointment of Mr. V Sundaresan as Additional Independent Director for a 5-year term starting December 22, 2025Appointee previously served as CFO of TTK Prestige Ltd and has nearly 40 years of leadership experience in finance and auditShareholder approval to be sought through Postal Ballot with remote e-voting from December 26, 2025, to January 24, 2026Final results of the postal ballot and director appointment confirmation expected by January 28, 2026
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive governance move, bringing in a seasoned financial expert familiar with the group's operations. No immediate portfolio changes are required.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
